<div id="readability-page-1"><p>SG Americas Securities LLC increased its position in  Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 419.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 115,640 shares of the pharmaceutical company's stock after buying an additional 93,367 shares during the quarter. SG Americas Securities LLC's holdings in Vertex Pharmaceuticals were worth $51,483,000 as of its most recent filing with the Securities and Exchange Commission.</p><ul><li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li></ul><p>Several other large investors also recently made changes to their positions in VRTX. United Services Automobile Association bought a new stake in  Vertex Pharmaceuticals during the first quarter valued at $2,933,000.  Lee Johnson Capital Management LLC bought a new position in  Vertex Pharmaceuticals in the 2nd quarter worth approximately $721,000.  Police &amp; Firemen s Retirement System of New Jersey increased its holdings in shares of  Vertex Pharmaceuticals by 3.7% during the second quarter. Police &amp; Firemen s Retirement System of New Jersey now owns 39,035 shares of the pharmaceutical company's stock valued at $17,378,000 after purchasing an additional 1,393 shares during the period.  Bailard Inc. increased its stake in  Vertex Pharmaceuticals by 0.5% during the 2nd quarter. Bailard Inc. now owns 38,147 shares of the pharmaceutical company's stock valued at $16,983,000 after buying an additional 200 shares during the period.  Finally, SteelPeak Wealth LLC acquired a new stake in  Vertex Pharmaceuticals in the second quarter worth approximately $10,059,000. Institutional investors and hedge funds own  90.96% of the company's stock. </p><div><p><span></span><span>Get <strong>Vertex Pharmaceuticals</strong> alerts:</span></p></div><h2>Vertex Pharmaceuticals Stock Performance</h2><p>Shares of VRTX stock opened at $437.15 on Friday. The company has a market capitalization of $110.91 billion, a P/E ratio of 31.25 and a beta of 0.36. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.68. The company's 50 day moving average price is $408.04 and its two-hundred day moving average price is $427.84. </p><ul><li>Best Biotech Stocks to Buy in 2025</li></ul><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period last year, the company earned $4.38 earnings per share. Vertex Pharmaceuticals's quarterly revenue was up 11.0% on a year-over-year basis.  Vertex Pharmaceuticals has set its FY 2025 guidance at  EPS. Analysts forecast that  Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year. </p><h2>Analysts Set New Price Targets</h2><p>Several research analysts have issued reports on VRTX shares. UBS Group decreased their price target on shares of Vertex Pharmaceuticals from $553.00 to $546.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, November 7th. Morgan Stanley reduced their price objective on shares of Vertex Pharmaceuticals from $439.00 to $438.00 and set an &#34;equal weight&#34; rating for the company in a research note on Friday, October 10th. Wall Street Zen downgraded Vertex Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Friday, August 22nd. Stifel Nicolaus cut their price target on Vertex Pharmaceuticals from $455.00 to $445.00 and set a &#34;hold&#34; rating for the company in a report on Tuesday, November 4th. Finally, Cantor Fitzgerald decreased their price target on Vertex Pharmaceuticals from $535.00 to $485.00 and set an &#34;overweight&#34; rating on the stock in a research note on Tuesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eleven have assigned  a Hold rating to the stock. According to MarketBeat.com, Vertex Pharmaceuticals  has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $491.95.</p><ul><li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li></ul><p><b>Read Our Latest Stock Analysis on Vertex Pharmaceuticals</b></p><h2>Vertex Pharmaceuticals Company Profile</h2> (Free Report)<p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Vertex Pharmaceuticals</li><li>What is a Secondary Public Offering? What Investors Need to Know</li><li>MarketBeat Week in Review – 11/10 - 11/14</li><li>What Does Downgrade Mean in Investing?</li><li>Are These 3 Oversold Tech Giants Ready to Rebound?</li><li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025 </li><li>If You Wait for the Dip,  Micron Technology Could Leave You Behind</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VRTX

<p>SG Americas Securities LLC significantly increased its stake in Vertex Pharmaceuticals by 419.2% in Q2, now holding 115,640 shares valued at $51.48 million. Other investors also adjusted their positions in Vertex. The company's stock opened at $437.15 with a market cap of $110.91 billion. Analysts have issued mixed ratings, with a consensus price target of $491.95. Vertex reported Q3 earnings of $4.80 per share, surpassing estimates, with revenue up 11% year-over-year.</p>

SG Americas Securities LLC Grows Position in Vertex Pharmaceuticals Incorporated $VRTX